Pfizer says its COVID-19 pill cuts disease's worst risks by 89%
Based on the strength of the trial's results, Pfizer says it will ask the FDA for emergency use authorization rather than enroll more people for clinical trials.
Pfizer says that its COVID-19 pill reduced the risk of hospitalization or death by 89%, in a clinical trial that tested the drug in adults with the disease who were also in high-risk health groups.
The oral that was approved in the U.K. Thursday, Pfizer said its drug showed good results when administered within the first five days of the first COVID-19 symptoms.
